Histiocytic sarcoma (HS) is an incurable aggressive tumor, and no consensus has been made on the treatment due to its rare occurrence. Since dogs spontaneously develop the disease and several cell lines are available, they have been advo...
Veterinary and comparative oncology 2023年2月 [査読有り]
Canine prostate cancer (cPCa) is a malignant neoplasm with no effective therapy. The BRAF V595E mutation, corresponding to the human BRAF V600E mutation, is found frequently in cPCa. Activating BRAF mutations are recognized as oncogenic drivers, a...
BMC veterinary research 18(1) 384-384 2022年11月 [査読有り]
BACKGROUND: Multiple myeloma (MM) is an uncommon neoplasm in cats. There is no established standard of treatment due to the rare occurrence of this disease in cats. Bortezomib is a proteasome inhibitor that serves as the first-line drug for MM in ...
Veterinary and Comparative Oncology 20(1) 109-117 2022年3月 [査読有り]
Canine histiocytic sarcoma (HS) is an aggressive and highly metastatic neoplasm. Mutations in src homology 2 domain-containing phosphatase 2 (SHP2; encoded by PTPN11), which recently have been identified in canine HS tumour cells, could be attract...
Hiroyuki Tani Ryo Miyamoto Syunya Noguchi Sena Kurita Tomokazu Nagashima Masaki Michishita Naoko Yayoshi Kyoichi Tamura Makoto Bonkobara
BMC veterinary research 17(1) 147-147 2021年4月 [査読有り]
BACKGROUND: Canine malignant melanoma is highly aggressive and generally chemoresistant. Toceranib is a kinase inhibitor drug that inhibits several tyrosine kinases including the proto-oncogene receptor tyrosine kinase KIT. Although canine maligna...
学長
獣医学部